Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab by Sznol, Mario et al.
POSTER PRESENTATION Open Access
Markers of inflammation are associated with
clinical outcomes in patients with metastatic
renal cell carcinoma treated with nivolumab
Mario Sznol1*, Mayer Fishman2, Bernard Escudier3, David F McDermott4, Harriet Kluger5, Walter M Stadler6,
Jose Perez-Gracia7, Douglas G McNeel8, Brendan D Curti9, Michael R Harrison10, Elizabeth R Plimack11,
Leonard Appleman12, Lawrence Fong13, Charles G Drake14, Tina C Young15, Scott D Chasalow15,
Petra Ross-MacDonald15, Jason S Simon15, Dana Walker15, Toni K Choueiri16
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC
2015)
National Harbor, MD, USA. 4-8 November 2015
Background
In previously treated patients with metastatic renal cell
carcinoma (mRCC), the programmed death-1 (PD-1)
inhibitor antibody nivolumab demonstrated objective
response rates of 20%–22% and median overall survival
(OS) of 18.2– 25.5 months[1]. An exploratory biomarker
analysis of baseline and on-therapy changes was con-
ducted to investigate the relationship between the clinical
and immunomodulatory activity of nivolumab.
Methods
Patients with 1–3 prior therapies for mRCC received nivo-
lumab 0.3, 2, or 10 mg/kg IV every 3 weeks (Q3W); treat-
ment-naïve patients received 10 mg/kg IV Q3W. Biopsies
and peripheral blood mononuclear cells were obtained at
baseline and cycle 2 day 8. Tumor burden reduction was
defined as a ≥20% decrease. Gene expression data were
obtained on Affymetrix U219. OS parameters were esti-
mated by the Kaplan-Meier method or by Cox proportional
hazards regression. PD-1 ligand 1 (PD-L1) expression was
measured by tumor membrane immunohistochemical
staining (28-8 antibody; Dako) in baseline biopsies. Serum-
soluble factors were quantified using a Luminex multiplex
panel (Myriad Rules-Based Medicine). T cell receptor
sequencing was conducted with the immunoSEQ assay
(Adaptive Biotechnologies).
Results
91 patients were treated. 59 baseline and 55 on-therapy
biopsies were evaluable for gene expression, with 42
matched samples. Patients with tumor burden reduction
had differential expression (>1.3-fold, P < 0.01, q-value <
0.16) of 311 genes at baseline (n = 13) and 779 genes on-
therapy (n = 11) compared with patients without tumor
burden reduction, including higher expression of tran-
scripts associated with cell-mediated immunity. CTLA-4,
TIGIT, and PD-L2 transcripts were present at higher
levels on-therapy in patients with tumor burden reduction.
Table 1 summarizes OS and OS by PD-L1 expression.
18/56 biopsies (32%) had ≥5% PD-L1 expression. Among
serum-soluble factors, recognized prognostic markers
(VEGF, ICAM1, VCAM1, TIMP1) were associated with
OS. Based on T cell sequencing, increased tumor T cell
counts and decreased blood T cell clonality at baseline
were associated with longer OS.
Conclusions
Immune markers at baseline and on-therapy suggest pre-
existing adaptive immunity is associated with nivolumab-
induced tumor regression. Upregulation of immune
checkpoint molecules provides rationale for study of
nivolumab and ipilimumab combination in mRCC. A
minimal difference in OS by PD-L1 expression was
observed for up to 2 years.
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Table 1
Median OS, mo (95% CI) OS rate, % (95% CI)
1-yr 2-yr
Treatment group
0.3 mg/kg (n=22) 16.4 (10.1-NR) 71 (47-86) 44 (22-64)
2.0 mg/kg (n=22) NR 72 (48-86) 61 (36-78)
10 mg/kg (n=23) 25.2 (12.0-NR) 74 (48-88) 51 (27-71)
10 mg/kg (naïve) (n=24) NR 81 (57-92) 76 (51-89)
PD-L1 expression
≥5% (n=18) NR 71 (44-87) 64 (37-82)
<5% mg/kg (n=38) 23.4 (13.1-33.3) 71 (52-83) 48 (30-64)
NR = not reached
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